We are delighted to announce that 80 new research participants were enrolled in the EPAD Longitudinal Cohort Study (LCS) in June. We were thus able to continue the positive trend of increasing recruitment on a monthly basis, as it made June our most successful month to date  exceeding the 75 research participants enrolled in May and the 73 in April.

Congratulations are due to VUmc (Amsterdam, Netherlands) as the team screened 15 research participants in June for their inclusion in the EPAD study making it the most successful centre this month. Congratulations to the whole team (pictured above at the General Assembly meeting in Amsterdam with Lisa Vermunt, Silvia Ingala, Pieter-Jelle Visser and Philip Scheltens missing in the photo).

Philip Scheltens, Director of the Alzheimer Centre was delighted by the success of his team: “The EPAD project will create the largest trial ready cohort for early stage AD trials in the world. Its setup and design, in combination with the proof of concept studies that will start next year, makes it a unique and rich source of relevant patient data. We at VUmc are thrilled to be a part of EPAD and consider it our duty to be frontrunner in inclusion. We expect our patients are anxious to start the first trial with new compounds and so are we.”

A special mention this month goes to José Luis Molinuevo’s team in Barcelona (Spain) who recruited 11 new research participants.

We are also pleased to have reached an exciting new milestone with over 800 screened research participants. Stay tuned for more news after the summer break in early September!